A detailed history of Silvant Capital Management LLC transactions in Natera, Inc. stock. As of the latest transaction made, Silvant Capital Management LLC holds 13,342 shares of NTRA stock, worth $2.25 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
13,342
Previous 13,722 2.77%
Holding current value
$2.25 Million
Previous $1.49 Million 14.14%
% of portfolio
0.08%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$97.75 - $129.67 $37,145 - $49,274
-380 Reduced 2.77%
13,342 $1.7 Million
Q2 2024

Jul 25, 2024

SELL
$85.28 - $112.6 $16,800 - $22,182
-197 Reduced 1.42%
13,722 $1.49 Million
Q1 2024

Apr 30, 2024

BUY
$59.21 - $92.9 $51,749 - $81,194
874 Added 6.7%
13,919 $1.27 Million
Q4 2023

Jan 25, 2024

SELL
$37.55 - $62.64 $77,503 - $129,288
-2,064 Reduced 13.66%
13,045 $817,000
Q3 2023

Oct 24, 2023

SELL
$43.4 - $62.52 $31,899 - $45,952
-735 Reduced 4.64%
15,109 $668,000
Q2 2023

Jul 25, 2023

BUY
$47.08 - $55.16 $49,339 - $57,807
1,048 Added 7.08%
15,844 $770,000
Q1 2023

Apr 26, 2023

SELL
$36.57 - $58.29 $11,007 - $17,545
-301 Reduced 1.99%
14,796 $821,000
Q4 2022

Jan 23, 2023

SELL
$34.17 - $47.91 $160,530 - $225,081
-4,698 Reduced 23.73%
15,097 $0
Q3 2022

Nov 09, 2022

SELL
$36.93 - $56.68 $3,582 - $5,497
-97 Reduced 0.49%
19,795 $868,000
Q2 2022

Aug 03, 2022

SELL
$28.13 - $44.54 $112,266 - $177,759
-3,991 Reduced 16.71%
19,892 $705,000
Q1 2022

May 05, 2022

SELL
$30.32 - $91.33 $5,942 - $17,900
-196 Reduced 0.81%
23,883 $972,000
Q4 2021

Feb 07, 2022

BUY
$86.26 - $119.0 $1.26 Million - $1.74 Million
14,586 Added 153.65%
24,079 $2.25 Million
Q3 2019

Nov 12, 2019

BUY
$25.38 - $34.89 $240,932 - $331,210
9,493 New
9,493 $311,000

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $16.3B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Silvant Capital Management LLC Portfolio

Follow Silvant Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvant Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvant Capital Management LLC with notifications on news.